Press Releases

Press Releases
Date Title and Summary View
Aug 2, 2016 NORCROSS, Ga., Aug. 02, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces the completion of patient recruitment in its Phase 2 clinical trial with GR-MD-02 in patients with non-alcoholi...
Jul 13, 2016 Dr. Traber to speak on Galectin Therapeutics' Development of GR-MD-02 for treatment of human disease NORCROSS, Ga.--(BUSINESS WIRE)-- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today a...
Jul 12, 2016 NORCROSS, Ga.--(BUSINESS WIRE)-- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the Company has received a Notice of Allowance from the Australian Government Patent Office for its patent ap...
Jun 2, 2016 NORCROSS, Ga., June 02, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, reports that GR-MD-02, its development-stage galectin-3 (gal-3) inhibitor, has shown a positive effect on vascular remodeling in an anim...
May 16, 2016 A significant clearing of psoriasis in first four patients prompts the extension of treatment for an additional 12 weeks Conference call to be held tomorrow at 9:00 a.m. Eastern time NORCROSS, Ga., May 16, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeu...
May 11, 2016 NORCROSS, Ga., May 11, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces the completion of enrollment in its Phase 2 clinical trial with GR-MD-02 in patients with non-alcoholic steatohe...
May 10, 2016 NORCROSS, Ga., May 10, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported financial results for the three months ended March 31, 2016. These results are included in the Company's Form 10-Q, which ha...
May 5, 2016 NORCROSS, Ga., May 05, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, has received notification that its collaborative abstract with investigators at Augusta University "Galectin-3 Mediates Vascular Remode...
Apr 7, 2016 NORCROSS, Ga., April 07, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that Peter G. Traber, M.D., the Company's president, chief executive officer and chief medical officer, wi...
Mar 15, 2016 NORCROSS, Ga., March 15, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported financial results for the year ended December 31, 2015. These results are included in the Company's Annual Report on Form ...
FirstPrevious
3
... NextLast
Add to Briefcase = add release to Briefcase